KR960013368A - Anti-cancer activity enhancing composition containing tolyrin - Google Patents

Anti-cancer activity enhancing composition containing tolyrin Download PDF

Info

Publication number
KR960013368A
KR960013368A KR1019950008470A KR19950008470A KR960013368A KR 960013368 A KR960013368 A KR 960013368A KR 1019950008470 A KR1019950008470 A KR 1019950008470A KR 19950008470 A KR19950008470 A KR 19950008470A KR 960013368 A KR960013368 A KR 960013368A
Authority
KR
South Korea
Prior art keywords
tolyrin
composition containing
pharmaceutical composition
cancer activity
enhancing composition
Prior art date
Application number
KR1019950008470A
Other languages
Korean (ko)
Other versions
KR0159642B1 (en
Inventor
이정준
김영호
김세은
김항섭
이성우
Original Assignee
김은영
한국과학기술연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 김은영, 한국과학기술연구원 filed Critical 김은영
Publication of KR960013368A publication Critical patent/KR960013368A/en
Application granted granted Critical
Publication of KR0159642B1 publication Critical patent/KR0159642B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

본 발명은 토릴린을 함유하는 항암제 활성중강용 조성물에 관한 것으로, 사상자로부터 분리, 정제된 토릴린 화합물, 그의 유도체 또는 약학적으로 허용되는 염을 유효성분으로 포함하는 약학 조성물은 항암제와 병용 추여할 때, 부작용 없이 다중약제내성을 극복하여 항암제의활성제의 홀성을 증강시킬 수 잇는 유용한 약물이다.The present invention relates to an anticancer active anti-cancer composition containing tolyrin, wherein the pharmaceutical composition comprising a tolyrin compound, a derivative thereof, or a pharmaceutically acceptable salt separated and purified from a casualty as an active ingredient may be combined with an anticancer agent. At this time, it is a useful drug that can overcome the multi-drug resistance without side effects and enhance the holiness of the anti-cancer agent.

Description

토릴린을 함유하는 항암제 활성 증강용 조성물Anti-cancer activity enhancing composition containing tolyrin

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음As this is a public information case, the full text was not included.

Claims (3)

토릴린 화합물, 그의 유도체 또는 약학적으로 허용되는 염을 포함하는, 다중약제내성을 조절하여 항암제의 활성을 증가시키기 위한 약학 조성물.A pharmaceutical composition for increasing the activity of an anticancer agent by regulating multi-drug resistance, including a tolyrin compound, a derivative thereof, or a pharmaceutically acceptable salt thereof. 제1항에 있어서, 상기조성물이 사상자로부터 추출된 토릴린 함유 분획인 것을 특징으로 하는 약학 조성물.The pharmaceutical composition according to claim 1, wherein the composition is a tolyrin-containing fraction extracted from a casualty. 제1항에 있어서, 빈브라스틴, 아드리아마이신 또는 탁솔에의해 유도된 내성을 극복하여 항암제의 활성을 증가시키기 위한 약학 조성물.A pharmaceutical composition according to claim 1 for increasing the activity of an anticancer agent by overcoming the resistance induced by vinblastine, adriamycin or taxol. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019950008470A 1994-10-19 1995-04-12 Torilin-containing composition for enhancing activity of anti-cancer agents KR0159642B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR19940026695 1994-10-19
KR94-26695 1994-10-19

Publications (2)

Publication Number Publication Date
KR960013368A true KR960013368A (en) 1996-05-22
KR0159642B1 KR0159642B1 (en) 1998-12-01

Family

ID=26630625

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950008470A KR0159642B1 (en) 1994-10-19 1995-04-12 Torilin-containing composition for enhancing activity of anti-cancer agents

Country Status (1)

Country Link
KR (1) KR0159642B1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100715886B1 (en) * 2005-09-26 2007-05-09 우석대학교 산학협력단 A composition containing torilin for preventing and treating arrhythmia, and a method for preparing the same
WO2021162505A1 (en) 2020-02-13 2021-08-19 주식회사 파마진 Compound isolated from torilidis fructus, and anticancer pharmaceutical composition containing same as active ingredient

Also Published As

Publication number Publication date
KR0159642B1 (en) 1998-12-01

Similar Documents

Publication Publication Date Title
FR2708606B1 (en) N-phenylalkylindol-2-one derivatives, their preparation, pharmaceutical compositions containing them.
DE69920757D1 (en) IMMUNE SUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES
MX9307644A (en) MEDICATION INCLUDING 2-AMINO-6-N-PROPIL-AMINO-4,5, 6, 7, -TETRAHIDROBENZOTIAZOLE WITH ANTIDEPRESSIVE EFFECT.
KR930702002A (en) Apoptosis Modulators
KR890015742A (en) Topical preparations for the treatment of diseases
CA2270955A1 (en) Pharmaceutical composition containing morphinan derivative for treating drug dependence
KR910005841A (en) Pharmacological composition acting on skin microcirculation
BR9807145A (en) 2-methoxyimino-2- (pyridinyloxymethyl) phenylacetamides with carboxylic acid derivatives in the pyridine ring as fungicides.
CO5190674A1 (en) TREATMENT OF NEUROTIC DISORDERS NEUROTIC DISORDERS
MD1560F2 (en) Cyclic compounds, pharmaceutical compositions on base thereof and methods of treatment of infections or diseases provoked by retroviruses.
KR910004191A (en) Renal disease treatment
DE69931378D1 (en) CHINAZOLINE DERIVATIVES AND THERAPEUTIC USES THEREOF
KR960013368A (en) Anti-cancer activity enhancing composition containing tolyrin
KR970061248A (en) 1, 1, 2-triphenylbut-1-ene derivative for the treatment of Alzheimer's disease
KR910016327A (en) Use of Teniad as Inhibitor of Elastase Release by Neutrophils
KR940011006A (en) Periodontal disease prevention and therapeutic composition comprising golden extract as an active ingredient
KR960000917A (en) Polyoxypregnan Glycosides with Multiple Drug Resistance Regulation of Cancer Cells Extracted from Baek Shou
KR960003717A (en) Use of elliprodil and its enantiomers for the manufacture of a medicament useful for the prevention of peripheral neuropathy caused by anticancer agents
KR910000115A (en) External preparation to inhibit melanin production
KR880009644A (en) Weak composition for treating ulcerative bowel disease
KR920007626A (en) How to use benzo [b] thiophene-2-carboxyimideamide derivative
KR920019349A (en) Use of R (+)-3-amino-1-hydroxy-pyrrolidin-2-one to treat anxiety
KR940002219A (en) N-substituted carbonyl-5-hydroxyanthranilic acid derivatives
KR950016756A (en) Fatigue Recovery Composition
PT986390E (en) PHARMACEUTICAL COMPOSITIONS CONTAINING CYCONHONINE CYCLORIDRATE

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20030813

Year of fee payment: 6

LAPS Lapse due to unpaid annual fee